Abstract
Purpose: To assess the efficacy of the Defocus Incorporated Multiple Segments (DIMS) spectacle lens for myopia control and its impact on vision-related quality of life in Chinese children over a 1-year period. Methods: This randomized double-blind prospective controlled clinical trial enrolled 176 myopic subjects aged between seven and 14 years who were randomly assigned into the DIMS group or the control single-vision (SV) group. Refractive error and axial length measurements at baseline, three-, six-, nine-, and 12-month follow-up visits were monitored. The Quality of Life Impact of Refractive Correction (QIRC) questionnaire was used to evaluate the vision-related quality of life at baseline and at 12 months postintervention. Results: Of the initial cohort, a total of 151 children successfully completed the study (DIMS n = 72; SV n = 79). Baseline characteristics were similar between both groups. Average axial elongation and myopia progression after 1 year were 0.17 (95% CI 0.13-0.20) mm and -0.27 (95% CI -0.36 to -0.18) D in the DIMS group and 0.30 (95% CI 0.26-0.33) mm and -0.55 (95% CI -0.64 to -0.47) D in the SV group. The mean differences in axial elongation and myopia progression were 0.13 mm (95% CI 0.08-0.18 mm, p < 0.001) and -0.28 D (95% CI -0.41 to -0.15 D, p < 0.001) between the two groups. No significant difference in the QIRC score was found between the DIMS and SV groups (55.30 (95% CI 53.17-56.90) versus 54.20 (95% CI 51.99-56.41), p=0.854)). Conclusion: The use of DIMS lenses in children was found to slow down myopia progression compared to SV lenses, without negatively affecting their overall quality of life. Trial Registration: Clinical Trial Registry identifier: ChiCTR2000037443.